Dr. Hope on Using 68Ga-PSMA-11 to Detect Pelvic Nodal Metastasis in Prostate Cancer

Video

Thomas Hope, MD, discusses the rationale for using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Thomas Hope, MD, an associate professor of radiology and director of Molecular Therapy for the Molecular Imaging and Therapeutics Clinical Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco (UCSF), discusses the rationale for using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

A prospective phase 3 trial evaluated the sensitivity and specificity of the radiotracer 68Ga-PSMA-11 in detecting pelvic nodal metastases at the time of radical prostatectomy in men with intermediate- or high-risk prostate cancer.

Previously published data from Europe demonstrated the utility of Ga68-PSMA-11 in this setting, says Hope.

Positive findings from this study support the utility of this radiotracer, as well as the submission of a New Drug Application to the FDA, concludes Hope.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD